Stryker OP-1 royalties
This article was originally published in The Gray Sheet
Curis enters agreement eliminating all future royalties to Stryker related to osteogenic protein-1 sales, the firms say Oct. 1. Under the terms of the deal, Curis receives a one-time $14 mil. cash transfer from Stryker, which will amortize the payment over 15 years...
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.